Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 4(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00030459Phase 2Unknown

Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma

Role: lead

NCT00376662Phase 4Completed

HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids.

Role: lead

NCT00367913Phase 4Completed

Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease

Role: lead

NCT00365950Phase 4Completed

3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE

Role: lead

All 4 trials loaded